Capricor Therapeutics, Inc. (CAPR) stock
Close on Nov 11, 2026Market cap $652.32MP/E –Yield –
Capricor Therapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$132.66M. At the latest close the market valued the company at $652.32M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $652.32M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.11
- Dividend yield
- –
- Free cash flow yield
- -20.34%
Fundamentals
- Revenue
- $0
- Net income
- -$147.50M
- EPS, diluted
- -$2.64
- Free cash flow
- -$132.66M
- Book value per share
- $3.61
- Diluted shares
- 58M
Trading
- Next earnings
- Mar 11, 2027 (estimated, after the close)
- Previous close
- $8.87
- Open
- $9.65
- Day's range
- $8.98 – $11.23
- Volume
- 10,070,070
- Average volume (20 days)
- 3,815,457
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.21
- 52-week range
- $2.96 – $40.37
- RSI (14 days)
- 69.4
- Volatility (1 year)
- 394.3%
- Relative volume
- 1.75×
- WACC
- 10.9%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CAPR | S&P 500 | Difference | CAPR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +43.3% | -2.4% | +45.7 pts | ||
| 3 months | +185.5% | -1.2% | +186.6 pts | ||
| Year to date | -61.1% | +12.3% | −73.4 pts | ||
| 1 year | +81.0% | +12.4% | +68.5 pts | ||
| 3 years | +300.7% | +78.8% | +221.9 pts | +58.8% | +21.4% |
| 5 years | +223.3% | +75.2% | +148.2 pts | +26.5% | +11.9% |
| 10 years | -58.7% | +311.1% | −369.9 pts | -8.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Capricor Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- News
- News
- News
About Capricor Therapeutics
Pharmaceutical Preparations
Capricor Therapeutics is a biotechnology company that develops cell and exosome therapeutics for rare diseases and conditions with significant unmet medical need, primarily Duchenne muscular dystrophy. Its lead product candidate is Deramiocel, an investigational cardiac-derived cell therapy aimed at reducing cardiac and skeletal muscle decline in individuals with muscular dystrophy. The company also develops an engineered exosome platform called StealthX for vaccines and targeted therapies, including a candidate for COVID-19. Since Capricor currently has no approved commercial products, it collaborates with commercial partners and research institutions such as Nippon Shinyaku rather than selling directly to commercial consumers, targeting patients with severe degenerative disorders.
Company profile, executives and historyCapricor Therapeutics stock: common questions
What is Capricor Therapeutics's stock price?
CAPR closed at $11.22 on Nov 11, 2026, up 26.49% on the day. Over the past 52 weeks it traded between $2.96 and $40.37.
What is Capricor Therapeutics's market cap?
Capricor Therapeutics was worth $652.32M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CAPR's P/E ratio?
Capricor Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.64), so it has no meaningful P/E ratio.
How much revenue does Capricor Therapeutics make?
Capricor Therapeutics reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Capricor Therapeutics pay a dividend?
No. Capricor Therapeutics has not paid a cash dividend over the last twelve months.
When does Capricor Therapeutics report earnings next?
Capricor Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CAPR stock performed over the past year?
Including dividends, CAPR returned +81.0% over the past year, against +12.4% for the S&P 500.
How many CAPR shares are sold short?
19M shares were sold short at the latest FINRA report, 32.79% of the float, or 7.4 days of average trading volume.
Who are Capricor Therapeutics's competitors?
Companies most similar to Capricor Therapeutics by business, industry and size include PRQR, ARCT, QURE, CELU, KROS.
See a number that looks wrong?